Format

Send to

Choose Destination
Diagn Microbiol Infect Dis. 2015 Oct;83(2):183-6. doi: 10.1016/j.diagmicrobio.2015.06.011. Epub 2015 Jun 23.

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).

Author information

1
JMI Laboratories, North Liberty, IA, USA. Electronic address: helio-sader@jmilabs.com.
2
JMI Laboratories, North Liberty, IA, USA.

Abstract

We evaluated the in vitro activity of tigecycline and selected comparator agents tested against carbapenem-resistant Enterobacteriaceae (CRE) isolated from European medical centers. A total of 14,286 clinically significant nonduplicate Enterobacteriaceae isolates were collected from 18 European countries in 2010-2013. Susceptibility testing was performed by CLSI broth microdilution method, and isolates with a meropenem or imipenem MIC at ≥4μg/mL were categorized as CRE. Selected CRE strains were screened for acquired carbapenemases by multiplex polymerase chain reaction and sequencing. Overall, 2.0% (280/14,286) of Enterobacteriaceae strains were CRE. The highest CRE occurrence was observed in Poland (17.3%; 70/405), followed by Italy (7.5%, 130/1,743), Greece (7.4%; 45/605), and Romania (5.0%; 8/157). The most common CRE species were Klebsiella pneumoniae (242; 86.4%) and Enterobacter cloacae (22; 7.9%), and the most common carbapenemases were KPC-2/3 (85.4%) and VIM-type (12.5%). Only tigecycline (88.6% susceptible) and colistin (73.9%) exhibited good in vitro activity (>70.0%) against CRE strains.

KEYWORDS:

Carbapenem resistance; KPC; VIM; beta-lactamases

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center